Stem Cell Research - HLHS
Jazmine Price and her daughter, Khylee Douglas - UMMC’s first HLHS Stem Cell Trial Patient
Sunjay Kaushal, M.D., Ph.D., is leading a clinical trial to address hypoplastic left heart syndrome (HLHS), a life-threatening congenital heart condition in newborn babies. If left untreated, HLHS is fatal in the first weeks of life. Babies with HLHS are born with an underdeveloped left heart which is not strong enough to properly circulate blood.
Currently, there is only palliative surgery for this condition, which has limited outcomes. Through an ongoing clinical trial using stem cells, Dr. Kaushal and the heart team at the University of Maryland Children’s Heart Program are taking major, ground-breaking steps to strengthen the heart function in HLHS patients.
The condition leaves the left ventricle underdeveloped, not strong enough to function correctly or properly circulate blood. The Phase I trial, the first of its kind in the world, uses stem cells as a way to strengthen the right, stronger side of the patient's heart.
Stem Cell Discussion with Dr. Sunjay Kaushal
In this video, Sunjay Kaushal, MD, PhD, discusses how stem cells work and why he decided to use them in a clinical trial to treat babies with hypoplastic left heart syndrome (HLHS).
Pediatric Cardiac Surgery Lab Tour with Dr. Sunjay Kaushal
Follow Dr. Kaushal during a tour of the Pediatric Cardiac Surgery Lab, where Dr. Kaushal and his team are doing research on the use of stem cells in babies with hypoplastic left heart syndrome (HLHS).